Sandoz recalls China-made blood pressure drug
Novartis said its Sandoz division is recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 12, 2018 Category: Pharmaceuticals Source Type: news
Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)
Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losartan, USP manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. Sandoz Inc. Losartan Potassium Hydrochlorothiazide product is manufactured by Lek Pharmaceuticals dd, Ljubljana, Slovenia. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a probable human carcinoge...
Source: Food and Drug Administration - November 9, 2018 Category: Food Science Source Type: news
Novartis division Sandoz recalls one lot of blood pressure drug
Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Losartan vs. Valsartan (Differences between Side Effects and Uses)
Title: Losartan vs. Valsartan (Differences between Side Effects and Uses)Category: MedicationsCreated: 9/21/2018 12:00:00 AMLast Editorial Review: 9/21/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 21, 2018 Category: Drugs & Pharmacology Source Type: news
Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up
Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 7, 2018 Category: Food Science Source Type: news
Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to product/label mix-up
PISCATAWAY, N.J., Sept. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodiu... Biopharmaceuticals, FDA, Product Recall Camber Pharmaceuticals, Montelukast, Losartan (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 6, 2018 Category: Pharmaceuticals Source Type: news
Label Mix-Up Prompts Montelukast Recall Label Mix-Up Prompts Montelukast Recall
Pill bottles that are labeled as montelukast sodium tablets but actually contain the antihypertensive losartan potassium are being recalled.News Alerts (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 31, 2018 Category: Internal Medicine Tags: Pulmonary Medicine News Alert Source Type: news
losartan (Cozaar)
Title: losartan (Cozaar)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 6/22/2018 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - June 22, 2018 Category: Cardiology Source Type: news
New findings about why losartan is effective in treating Marfan syndrome may reshape our thinking about patient management
(Elsevier) Progressive dilation of the aortic root is considered one of the most serious manifestations of Marfan syndrome. The antihypertensive losartan is one of the two medications recommended by current guidelines attenuate the progression of this aortic enlargement, but which medication works best is still controversial. A new report in The American Journal of Pathology confirms losartan's efficacy but finds that the underlying mechanism of action is different than previously thought, opening up new possibilities for improvements in Marfan syndrome management. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 9, 2018 Category: Biology Source Type: news
Hyzaar (Losartan Potassium-Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 27, 2017 Category: Drugs & Pharmacology Source Type: news
Losartan Does Not Reduce Lung Injury in Hospitalized COVID - 19 Patients
No significant impact on imputed arterial partial pressure of oxygen to fraction of inspired oxygen ratio at seven days (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 12, 2017 Category: Respiratory Medicine Tags: Infections, Pharmacy, Pulmonology, Critical Care, Journal, Source Type: news
Commercialization of Generics Impacts Adverse Event Rates
Adverse events up for generic users of losartan, valsartan, candesartan in month of commercialization (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 4, 2017 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Geriatrics, Gynecology, Internal Medicine, Emergency Medicine, Nephrology, Neurology, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news
Cozaar (Losartan Potassium) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 8, 2016 Category: Drugs & Pharmacology Source Type: news
In newly diagnosed hypertension with OSA, adding CPAP augmented the benefits of losartan
In patients with new-onset hypertension and obstructive sleep apnea, continuous positive airway pressure (CPAP) therapy plus antihypertensive treatment with losartan led to reductions in systolic... (Source: Clinical Neurology News)
Source: Clinical Neurology News - March 4, 2016 Category: Neurology Source Type: news
In newly diagnosed hypertension with OSA, adding CPAP augmented the benefits of losartan
In patients with new-onset hypertension and obstructive sleep apnea, continuous positive airway pressure (CPAP) therapy plus antihypertensive treatment with losartan led to reductions in systolic... (Source: Family Practice News)
Source: Family Practice News - March 4, 2016 Category: Primary Care Source Type: news
